Akebia Therapeutics Announces Preliminary Full-Year 2018 Financial Results and Business Highlights
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/24/2026
- S&P 500 ends marginally lower as investors focus on US-Iran war
- Oracle triggers force majeure on massive 'Project Jupiter' data center
- Oil gains on little sign of progress in US-Iran talks
- S&P 500 history shows strong gains across Fed hiking cycles: BCA
- JPMorgan upgrades CoreWeave on stronger compute pricing
- Plug Power COO resigns to join another company
- Bloom Energy falls as Oracle invokes force majeure on AI project
- Oracle triggers force majeure on massive 'Project Jupiter' data center
- Oracle Sends Force Majeure Notice Over New Mexico Data Center - Bloomberg
- Akamai signs $11.6B deal with Anthropic, up to $20B potential
Akebia Therapeutics (AKBA) Reports Q4 Revenues Miss
March 18, 2019 4:12 PM EDTAkebia Therapeutics (NASDAQ: AKBA) reported Q4 revenue for the quarter came in at $59.85 million versus the consensus estimate of $73.67 million.
2018 was a transformational year for Akebia, said John P. Butler, President and Chief Executive Officer of Akebia Therapeutics. We successfully executed a number of strategic initiatives to advance our mission, and with the recent completion of our merger with Keryx, we have... More
